Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Core Insights - Pfizer and Valneva's experimental Lyme disease vaccine demonstrated over 70% efficacy in late-stage trials, with specific efficacy rates of 73.2% and 74.8% in different analyses [1][3]. Company Developments - Pfizer plans to seek U.S. regulatory approval for the Lyme disease vaccine, named PF-07307405, as there is currently no approved vaccine available for this disease [2]. - Valneva anticipates that Pfizer will launch the vaccine in the second half of 2027, pending regulatory approval [4]. Industry Context - Lyme disease is transmitted through bites from infected blacklegged ticks, with symptoms including fever, headache, fatigue, and a characteristic skin rash [3]. - The CDC estimates that approximately 476,000 people are diagnosed and treated for Lyme disease annually in the U.S., while around 132,000 cases are reported each year in Europe [4].